12 October 2026 Argent BioPharma Advances Focused Immune Modulation and Inflammatory Disease Strategy Highlights: • Argent BioPharma consolidates its strategy around immune modulation and in?ammatory disease following the global licensing of CannEpil® • RGT-CA91980 established as the ...
Strategic Focus on Immune Modulation and Longevity
Filed with ASX ·
6ix hasn’t read this filing yet.
Earlier from Argent Biopharma
- Application for quotation of securities - RGT
- Execution of Loan Facility Agreement
- Argent Signs NLC Licence to Expand Antiviral Portfolio
- Proposed issue of securities - RGT
- Notification of cessation of securities - RGT
Later from Argent Biopharma
- Date of AGM and Closing Date for Director Nominations
- Notice of Annual General Meeting/Proxy Form
- Quarterly Activities/Appendix 4C Cash Flow Report
- RGT Executes Global Licence for Non-Core Cannabis Genetics
Follow Argent Biopharma into a list and get an email when it puts out news.
Follow Argent Biopharma